
PMC:7755033 / 6343-6676
Annnotations
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
---|---|---|---|---|---|
180 | 77-82 | Species | denotes | human | Tax:9606 |
181 | 94-98 | Species | denotes | CoVs | Tax:11118 |
189 | 148-158 | Chemical | denotes | nucleoside | MESH:D009705 |
190 | 168-178 | Chemical | denotes | remdesivir | MESH:C000606551 |
191 | 180-200 | Chemical | denotes | tenofovir disoproxil | MESH:D000068698 |
192 | 208-218 | Chemical | denotes | umifenovir | MESH:C086979 |
193 | 220-227 | Chemical | denotes | arbidol | MESH:C086979 |
194 | 233-243 | Chemical | denotes | lamivudine | MESH:D019259 |
195 | 245-248 | Chemical | denotes | 3TC | MESH:D019259 |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T46 | 24-268 | Sentence | denotes | Several antiviral therapies have been identified for human pathogenic CoVs including synthetic inhibitors of neuraminidase, nucleoside analogs, remdesivir, tenofovir disoproxil (TDF), umifenovir (arbidol) and lamivudine (3TC) (Li et al., 2005). |